13
Participants
Start Date
March 13, 2017
Primary Completion Date
October 25, 2019
Study Completion Date
January 23, 2020
Elotuzumab
Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
Pomalidomide
Pomalidomide PO at 3mg
Carfilzomib
Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
Dexamethasone
Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
Regional Cancer Care Associates MD LLC, Bethesda
Millennium Oncology Research Clinic, Pembroke Pines
James Berenson, MD, Inc, West Hollywood
California Cancer Associates for Research & Excellence (cCARE), Encinitas
Robert A. Moss, MD, FACP, Inc, Fountain Valley
Pacific Cancer Care, Monterey
Lead Sponsor
Oncotherapeutics
INDUSTRY